AR068414A1 - Formas polimorficas 1,2 y solvatada de (s) -2-((4- benzofuranil) carbonilaminometil)1-((4-2- metil-5-(4- fluorofenil)) tiazolil) carbonil) piperidina , composicion farmaceutica que las comprende y su uso para la preparacion de unmedicamento para el tratamimiento o profilaxis de trastornos relacionad - Google Patents
Formas polimorficas 1,2 y solvatada de (s) -2-((4- benzofuranil) carbonilaminometil)1-((4-2- metil-5-(4- fluorofenil)) tiazolil) carbonil) piperidina , composicion farmaceutica que las comprende y su uso para la preparacion de unmedicamento para el tratamimiento o profilaxis de trastornos relacionadInfo
- Publication number
- AR068414A1 AR068414A1 ARP080103950A ARP080103950A AR068414A1 AR 068414 A1 AR068414 A1 AR 068414A1 AR P080103950 A ARP080103950 A AR P080103950A AR P080103950 A ARP080103950 A AR P080103950A AR 068414 A1 AR068414 A1 AR 068414A1
- Authority
- AR
- Argentina
- Prior art keywords
- fluorophenyl
- methyl
- piperidine
- pharmaceutical composition
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Formas polimorficas 1, 2 y solvatada de (S)-2-((4-benzofuranil)carbonilaminometil)-1-((4-(2-metil-5-(4-fluorofenil)tiazolil)carbonil)piperidina, que tienen XRPD, DSC, espectros FT-IR y FT-Raman característicos. Composicion farmacéutica que las comprende. Su uso para la preparacion de un medicamento para el tratamiento o profilaxis de trastornos del sueno, depresion, trastornos del estado de ánimo, ansiedad, trastornos relacionados con sustancias y trastornos alimentarios. Reivindicacion 1: Una forma polimorfica de (S)-2-((4-benzofuranil)carbonilaminometil)-1-((4-(2-metil-5-(4-fluorofenil))tiazolil)carbonil)piperidina caracterizada porque es la Forma 1 y i) proporciona: un difractograma de difraccion de rayos X de polvo (XRPD) que comprende los siguientes picos segun cuadro (1); y ii) tiene un comienzo de fusion en el intervalo de 163-173°C, tal como se midio mediante análisis por DSC. Reivindicacion 6: Una forma polimorfica de (S)-2-((4-benzofuranil)carbonilaminometil)-1-((4-(2-metil-5-(4-fluorofenil))tiazolil)carbonil)piperidina de acuerdo con la reivindicacion 1, caracterizada porque es la Forma 2 y i) proporciona un difractograma de difraccion de rayos X de polvo (XRPD) que comprende los siguientes picos segun cuadro (2) y ii) tiene un comienzo de fusion en el intervalo de 113-123°C, tal como se midio mediante análisis por DSC. Reivindicacion 11: Una forma polimorfica de (S)-2-((4-benzofuranil)carbonilaminometil)-1-((4-(2-metil-5-(4-fluorofenil))tiazolil)carbonil)piperidina caracterizada porque es la Forma solvatada y i) proporciona: un difractograma de difraccion de rayos X de polvo (XRPD) que comprende los siguientes picos segun cuadro (3) y ii) tiene un comienzo de desolvatacion en el intervalo de 89-99°C, tal como se midio mediante análisis por DSC.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0717882.5A GB0717882D0 (en) | 2007-09-13 | 2007-09-13 | Novel pharmaceutical |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068414A1 true AR068414A1 (es) | 2009-11-18 |
Family
ID=38658914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103950A AR068414A1 (es) | 2007-09-13 | 2008-09-11 | Formas polimorficas 1,2 y solvatada de (s) -2-((4- benzofuranil) carbonilaminometil)1-((4-2- metil-5-(4- fluorofenil)) tiazolil) carbonil) piperidina , composicion farmaceutica que las comprende y su uso para la preparacion de unmedicamento para el tratamimiento o profilaxis de trastornos relacionad |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20100286201A1 (es) |
| EP (1) | EP2190842A1 (es) |
| JP (1) | JP2010539133A (es) |
| KR (1) | KR20100057035A (es) |
| CN (1) | CN101801968A (es) |
| AR (1) | AR068414A1 (es) |
| AU (1) | AU2008297126A1 (es) |
| BR (1) | BRPI0816757A2 (es) |
| CA (1) | CA2699472A1 (es) |
| CL (1) | CL2008002688A1 (es) |
| CO (1) | CO6260068A2 (es) |
| CR (1) | CR11306A (es) |
| DO (1) | DOP2010000066A (es) |
| EA (1) | EA201070361A1 (es) |
| GB (1) | GB0717882D0 (es) |
| MA (1) | MA31692B1 (es) |
| MX (1) | MX2010002895A (es) |
| PE (1) | PE20090639A1 (es) |
| TW (1) | TW200927748A (es) |
| UY (1) | UY31337A1 (es) |
| WO (1) | WO2009034133A1 (es) |
| ZA (1) | ZA201001083B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120101110A1 (en) * | 2010-10-26 | 2012-04-26 | Sangamesh Badiger | Diaza-spiro[5.5]undecanes |
| WO2017194548A1 (en) | 2016-05-10 | 2017-11-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE293101T1 (de) * | 2000-06-16 | 2005-04-15 | Smithkline Beecham Plc | Piperidine zur verwendung als orexin rezeptor antagonisten |
| US20060178307A1 (en) * | 2005-01-26 | 2006-08-10 | The Regents Of The University Of California | Modulation of NMDA receptor currents via orexin receptor and/or CRF receptor |
-
2007
- 2007-09-13 GB GBGB0717882.5A patent/GB0717882D0/en not_active Ceased
-
2008
- 2008-09-10 CL CL2008002688A patent/CL2008002688A1/es unknown
- 2008-09-11 AU AU2008297126A patent/AU2008297126A1/en not_active Abandoned
- 2008-09-11 CA CA2699472A patent/CA2699472A1/en not_active Abandoned
- 2008-09-11 WO PCT/EP2008/062064 patent/WO2009034133A1/en active Application Filing
- 2008-09-11 KR KR1020107005447A patent/KR20100057035A/ko not_active Application Discontinuation
- 2008-09-11 PE PE2008001590A patent/PE20090639A1/es not_active Application Discontinuation
- 2008-09-11 AR ARP080103950A patent/AR068414A1/es not_active Application Discontinuation
- 2008-09-11 JP JP2010524487A patent/JP2010539133A/ja not_active Withdrawn
- 2008-09-11 UY UY31337A patent/UY31337A1/es unknown
- 2008-09-11 BR BRPI0816757 patent/BRPI0816757A2/pt not_active IP Right Cessation
- 2008-09-11 US US12/677,614 patent/US20100286201A1/en not_active Abandoned
- 2008-09-11 EP EP08804029A patent/EP2190842A1/en not_active Withdrawn
- 2008-09-11 MX MX2010002895A patent/MX2010002895A/es unknown
- 2008-09-11 CN CN200880106870A patent/CN101801968A/zh active Pending
- 2008-09-11 TW TW097134783A patent/TW200927748A/zh unknown
- 2008-09-11 EA EA201070361A patent/EA201070361A1/ru unknown
-
2010
- 2010-02-15 ZA ZA201001083A patent/ZA201001083B/xx unknown
- 2010-02-26 DO DO2010000066A patent/DOP2010000066A/es unknown
- 2010-03-05 MA MA32671A patent/MA31692B1/fr unknown
- 2010-03-10 CR CR11306A patent/CR11306A/es unknown
- 2010-03-15 CO CO10030406A patent/CO6260068A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CO6260068A2 (es) | 2011-03-22 |
| CA2699472A1 (en) | 2009-03-19 |
| PE20090639A1 (es) | 2009-06-25 |
| CL2008002688A1 (es) | 2009-11-27 |
| MA31692B1 (fr) | 2010-09-01 |
| EP2190842A1 (en) | 2010-06-02 |
| MX2010002895A (es) | 2010-04-01 |
| ZA201001083B (en) | 2010-10-27 |
| TW200927748A (en) | 2009-07-01 |
| CN101801968A (zh) | 2010-08-11 |
| DOP2010000066A (es) | 2010-04-15 |
| US20100286201A1 (en) | 2010-11-11 |
| GB0717882D0 (en) | 2007-10-24 |
| EA201070361A1 (ru) | 2010-08-30 |
| AU2008297126A1 (en) | 2009-03-19 |
| BRPI0816757A2 (pt) | 2015-03-17 |
| CR11306A (es) | 2010-04-20 |
| WO2009034133A1 (en) | 2009-03-19 |
| UY31337A1 (es) | 2009-04-30 |
| JP2010539133A (ja) | 2010-12-16 |
| KR20100057035A (ko) | 2010-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA113051C2 (xx) | Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів | |
| MA32200B1 (fr) | Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation | |
| PE20120812A1 (es) | Compuestos vinil indazolilo | |
| EA021275B9 (ru) | Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания | |
| GEP20135983B (en) | 1-benzyl-3-hydroxymethylindazole derivatives and usage therein treatment of diseases based on mcp-1, cx3cr1 and p40 expression | |
| DOP2011000279A (es) | Derivados de benzofuranilo usados como inhibidores de glucoquinasa | |
| GEP20125666B (en) | HYDROXYMETHYL PYRROLIDINES AS β3 ADRENERGIC RECEPTOR AGONISTS | |
| MY149622A (en) | Pyrazoles as 11-beta-hsd-1 | |
| CL2013000884A1 (es) | El compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino, modulador del factor de crecimiento de fibroblastos (fgf); composicion farmaceutica, util en el tratamiento del cancer. | |
| CY1112725T1 (el) | Σπειροκυκλικα παραγωγα κυκλοεξανιου | |
| GEP20135927B (en) | 1-benzyl-3-hydroxymethylindaz-ole derivatives and usage thereat treatment of diseases based on mcp-1, cx3cr1 and p40 expression | |
| IT1391866B1 (it) | Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari. | |
| GEP20135959B (en) | Aryl piperazine and their usage as alpha2c antagonists | |
| MA32776B1 (fr) | Inhibiteurs de l'akt et de la p70 s6 kinase | |
| DOP2011000134A (es) | Lactamas como inhibidores de beta secretasa | |
| BR112018073951A2 (pt) | forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida | |
| EA201170512A1 (ru) | Композиция для перорального введения | |
| CU20100111A7 (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares | |
| SV2010003725A (es) | Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas | |
| UY29358A1 (es) | Tiazolidinonas, su preparacion y su uso como medicamento | |
| CO6491033A2 (es) | 5-3,4-dicloro-fenil- n-(2-hidroxi-cicloheexil)- 6-(2,2,2-trifluoro etoxi)- nicotinamida y sales de la misma, como agentes que elevan el colesterol hdl | |
| ATE495159T1 (de) | Diaminocyclohexan- und diaminocyclopentanderivate | |
| AR065565A1 (es) | Formas solidas de 1-metil-5-(2-(5-(trifluoro-metil)-1h-imidazol-2-il)-piridin-4-iloxi)-n-(4-(trifluoro-metil)-fenil)-1h-benzo-[d]-imidazol-2-amina con actividad inhibidora de cinasa raf y una composicion farmaceutica que las comprende. | |
| CU24011B1 (es) | Piperidinas 2-fenil-5-(1,2,4-oxadiazol-5-il) sustituidas | |
| AR068414A1 (es) | Formas polimorficas 1,2 y solvatada de (s) -2-((4- benzofuranil) carbonilaminometil)1-((4-2- metil-5-(4- fluorofenil)) tiazolil) carbonil) piperidina , composicion farmaceutica que las comprende y su uso para la preparacion de unmedicamento para el tratamimiento o profilaxis de trastornos relacionad |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |